RT Journal Article
SR Electronic
T1 Quantifying SARS-CoV-2 spread in Switzerland based on genomic sequencing data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.14.20212621
DO 10.1101/2020.10.14.20212621
A1 Sarah Nadeau
A1 Christiane Beckmann
A1 Ivan Topolsky
A1 Timothy Vaughan
A1 Emma Hodcroft
A1 Tobias Schär
A1 Ina Nissen
A1 Natascha Santacroce
A1 Elodie Burcklen
A1 Pedro Ferreira
A1 Kim Philipp Jablonski
A1 Susana Posada-Céspedes
A1 Vincenzo Capece
A1 Sophie Seidel
A1 Noemi Santamaria de Souza
A1 Julia M. Martinez-Gomez
A1 Phil Cheng
A1 Philipp P. Bosshard
A1 Mitchell P. Levesque
A1 Verena Kufner
A1 Stefan Schmutz
A1 Maryam Zaheri
A1 Michael Huber
A1 Alexandra Trkola
A1 Samuel Cordey
A1 Florian Laubscher
A1 Ana Rita Gonçalves
A1 Karoline Leuzinger
A1 Madlen Stange
A1 Alfredo Mari
A1 Tim Roloff
A1 Helena Seth-Smith
A1 Hans H. Hirsch
A1 Adrian Egli
A1 Maurice Redondo
A1 Olivier Kobel
A1 Christoph Noppen
A1 Niko Beerenwinkel
A1 Richard A. Neher
A1 Christian Beisel
A1 Tanja Stadler
YR 2020
UL http://medrxiv.org/content/early/2020/10/30/2020.10.14.20212621.abstract
AB Pathogen genomes provide insights into their evolution and epidemic spread. We sequenced 1,439 SARS-CoV-2 genomes from Switzerland, representing 3-7% of all confirmed cases per week. Using these data, we demonstrate that no one lineage became dominant, pointing against evolution towards general lower virulence. On an epidemiological level, we report no evidence of cryptic transmission before the first confirmed case. We find many early viral introductions from Germany, France, and Italy and many recent introductions from Germany and France. Over the summer, we quantify the number of non-traceable infections stemming from introductions, quantify the effective reproductive number, and estimate the degree of undersampling. Our framework can be applied to quantify evolution and epidemiology in other locations or for other pathogens based on genomic data.One Sentence Summary We quantify SARS-CoV-2 spread in Switzerland based on genome sequences from our nation-wide sequencing effort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSN and TS are supported by the Swiss National Science Foundation (grant number 31CA30_196267).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data used is available on https://www.gisaid.org/.